Elsevier, Food Safety Management: A Practical Guide for the Food Industry, Second Edition, 2023, pp 1041-1052
This chapter aligns with Goal 3: Good Health and Wellbeing and Goal 13: Climate Action by acknowledging the complexities and compounding effects of climate change on food safety.
This content aligns with Goal 3: Good Health as well as Goal 17: Partnership for the goals by reviewing equine-assisted services and the benefits to human therapy.
Elsevier, Translational SurgeryHandbook for Designing and Conducting Clinical and Translational Research2023, Pages 591-597
The extensive history of abuse and ongoing mistreatment of Black Americans continues to foster apprehension and distrust of healthcare providers. This has resulted in substantial barriers for modern healthcare to appropriately address the needs of Black patients. These concerns have been visibly manifested during the COVID-19 pandemic. This article supports WHO SDG 3 Good Health and Wellbeing and SDG10 Reduced Inequalities.
Elsevier, The Thinking Healthcare SystemArtificial Intelligence and Human Equity2023, Pages 99-129
Highlights the 21st century's fundamental “global health” reformulation of PubHealth and anticolonial resistance (to a perceived cultural imperialism of the West including in PubHealth) supporting SDG 3.
Elsevier, International Encyclopedia of Education, Fourth Edition, 2023, Pages 53-64
This chapter advances Goals 4, 10, and 3 by providing an overview of human rights education in formal and non-formal educational spaces and in professional settings. It includes current debates in the field around the pedagogy and practice of teaching human rights.
This content aligns with Goal 3: Good Health and Wellbeing by summarize the current understanding of inflammasome biology and the role of different inflammasomes in HIV pathogenesis with a focus on the recently described CARD8 inflammasome.
This content supports the SDG Goal 3: Good health and well-being by discussing the role of multifunctional metal nanoparticles as antiviral therapeutic agents and nanovaccines against different viruses, including human immunodeficiency virus, hepatitis viruses, influenza A virus, herpes simplex virus, and severe acute respiratory syndrome coronavirus 2.
